{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:27:27Z","timestamp":1786645647783,"version":"build-2736575974"},"reference-count":20,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R61AT013008; R01DK138121"],"award-info":[{"award-number":["R61AT013008; R01DK138121"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DOW","award":["PR200027 and PR240809"],"award-info":[{"award-number":["PR200027 and PR240809"]}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>Nitrofurantoin is considered a first-line antimicrobial agent by the AUA\/CUA\/SUFU Guideline and Infectious Disease Society of America (IDSA) Guideline for the treatment of acute uncomplicated simple cystitis in women. Nitrofurantoin has good oral bioavailability, high concentration in urine, and low serum and tissue concentrations. These characteristics result in minimal collateral damage to the microbial composition of other niches within the human body, such as the gut, that are essential in maintaining homeostasis. In addition, resistance to nitrofurantoin is uncommon owing to its interference with multiple bacterial cellular functions critical to survival. Large systematic reviews and meta-analyses have demonstrated that nitrofurantoin is noninferior to other commonly prescribed antibiotics for treatment of urinary tract infection (UTI). Recent data from a randomized controlled trial suggest that a 5-day course of nitrofurantoin may be more effective than a single dose of fosfomycin in the treatment of UTI. Therefore, nitrofurantoin is an ideal first-line agent in the management of UTI.<\/jats:p>","DOI":"10.1371\/journal.ppat.1014516","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T17:29:21Z","timestamp":1786642161000},"page":"e1014516","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nitrofurantoin treatment and prophylaxis for recurrent urinary tract infections in women: First-line for a reason"],"prefix":"10.1371","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6371-206X","authenticated-orcid":true,"given":"Alec","family":"Szlachta-McGinn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4192-7649","authenticated-orcid":true,"given":"A. Lenore","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"issue":"2","key":"ppat.1014516.ref001","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/JU.0000000000000296","article-title":"Recurrent uncomplicated urinary tract infections in women: AUA\/CUA\/SUFU guideline","volume":"202","author":"J Anger","year":"2019","journal-title":"J Urol"},{"issue":"5","key":"ppat.1014516.ref002","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cir102","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"K Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"1","key":"ppat.1014516.ref003","doi-asserted-by":"crossref","first-page":"14","DOI":"10.18773\/austprescr.2019.002","article-title":"Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems","volume":"42","author":"BJ Gardiner","year":"2019","journal-title":"Aust Prescr"},{"key":"ppat.1014516.ref004","unstructured":"Lewis D. Macrobid: Food and Drug Administration 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020064Orig1s029lbl.pdf"},{"issue":"3","key":"ppat.1014516.ref005","article-title":"Metabolites potentiate nitrofurans in nongrowing Escherichia coli","volume":"65","author":"SJ Aedo","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"ppat.1014516.ref006","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/jac\/dkv147","article-title":"Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials","volume":"70","author":"A Huttner","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"ppat.1014516.ref007","first-page":"000702","article-title":"Alterations in chromosomal genes nfsA, nfsB, and ribE are associated with nitrofurantoin resistance in Escherichia coli from the United Kingdom","volume":"7","author":"Y Wan","year":"2021","journal-title":"Microb Genom"},{"issue":"6","key":"ppat.1014516.ref008","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/jgs.14796","article-title":"How common are pulmonary and hepatic adverse effects in older adults prescribed nitrofurantoin?","volume":"65","author":"K Claussen","year":"2017","journal-title":"J Am Geriatr Soc"},{"key":"ppat.1014516.ref009","article-title":"\u201cCollateral damage\u201d from cephalosporin or quinolone antibiotic therapy","author":"DL Paterson","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"1","key":"ppat.1014516.ref010","doi-asserted-by":"crossref","DOI":"10.1002\/mbo3.1260","article-title":"Impact of antibiotics on the human microbiome and consequences for host health","volume":"11","author":"DV Patangia","year":"2022","journal-title":"Microbiologyopen"},{"issue":"7","key":"ppat.1014516.ref011","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1093\/jac\/dkv062","article-title":"Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota","volume":"70","author":"J Vervoort","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"ppat.1014516.ref012","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1128\/AAC.06060-11","article-title":"In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010","volume":"56","author":"GV Sanchez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"ppat.1014516.ref013","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00862-20","article-title":"Escherichia coli resistance to fluoroquinolones in community-acquired uncomplicated urinary tract infection in women: a systematic review","volume":"64","author":"AE Stapleton","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"ppat.1014516.ref014","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/jgs.13702","article-title":"2015 updated Beers criteria for potentially inappropriate medication use in older adults","volume":"63","author":"By the American Geriatrics Society Beers Criteria Update Expert P","year":"2015","journal-title":"J Am Geriatr Soc"},{"key":"ppat.1014516.ref015","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1159\/000512582","article-title":"The clinical efficacy of nitrofurantoin for treating uncomplicated urinary tract infection in adults: a systematic review of randomized control trials","volume":"105","author":"A Porreca","year":"2021","journal-title":"Urol Int"},{"issue":"17","key":"ppat.1014516.ref016","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jama.2018.3627","article-title":"Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial","volume":"319","author":"A Huttner","year":"2018","journal-title":"JAMA"},{"issue":"11","key":"ppat.1014516.ref017","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/S0149-2918(00)86734-X","article-title":"Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection","volume":"21","author":"GE Stein","year":"1999","journal-title":"Clin Ther"},{"issue":"6","key":"ppat.1014516.ref018","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF01871127","article-title":"Fosfomycin trometamol in a single dose versus seven days nitrofurantoin in the treatment of acute uncomplicated urinary tract infections in women","volume":"15","author":"E Van Pienbroek","year":"1993","journal-title":"Pharm World Sci"},{"issue":"6","key":"ppat.1014516.ref019","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cmi.2016.08.003","article-title":"Nitrofurantoin\u2019s efficacy and safety as prophylaxis for urinary tract infections: a systematic review of the literature and meta-analysis of controlled trials","volume":"23","author":"AE Muller","year":"2017","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"ppat.1014516.ref020","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.cmi.2021.05.048","article-title":"Nitrofurantoin 100 mg versus 50 mg prophylaxis for urinary tract infections, a cohort study.","volume":"28","author":"T Ten Doesschate","year":"2022","journal-title":"Clin Microbiol Infect"}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1014516","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T17:29:25Z","timestamp":1786642165000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1014516"}},"subtitle":[],"editor":[{"given":"John M","family":"Leong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1014516","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]}}}